|1.||Wallengren, N O: 2 articles (11/2000 - 04/2000)|
|2.||Jonsson, E: 2 articles (04/2000 - 01/2000)|
|3.||Reeders, J W: 1 article (11/2000)|
|4.||Kersting-Sommerhoff, B: 1 article (11/2000)|
|5.||Meusel, M: 1 article (11/2000)|
|6.||Annweiler, A A: 1 article (11/2000)|
|7.||Judmaier, W: 1 article (11/2000)|
|8.||Maier, A G: 1 article (11/2000)|
|9.||Schima, W: 1 article (11/2000)|
|10.||McGill, S: 1 article (04/2000)|
|1.||Rectal Neoplasms (Rectal Cancer)
01/01/2000 - "The aim of this study was to compare three imaging strategies for the diagnosis of local recurrence of rectal cancer: (a) MR imaging; (b) MR imaging after administration of enteral superparamagnetic particles (Ferristene); and (c) contrast-enhanced CT. "
11/01/2000 - "The aim of this study was to assess the accuracy of double-contrast magnetic resonance imaging (MRI) with rectal application of the superparamagnetic iron oxide contrast agent (SPIO) ferristene and IV gadodiamide for preoperative staging of rectal cancer. "
11/01/2000 - "Staging of rectal cancer by double-contrast MR imaging using the rectally administered superparamagnetic iron oxide contrast agent ferristene and IV gadodiamide injection: results of a multicenter phase II trial."
11/01/2000 - "High-viscosity ferristene formulations were superior to low-viscosity formulations in tumor staging (accuracy 90% vs 74%, P < 0.01). "
04/01/2000 - "Double-contrast (ferristene solution plus gadodiamide) MR imaging was superior to imaging with only ferristene-based contrast material and had a sensitivity of 100%, specificity of 70%, and accuracy of 90% in distinguishing tumor stages worse than Dukes A. "
|4.||Pancreatic Diseases (Pancreatic Disease)
|2.||ferric oxide (iron oxide)